These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 1332213)

  • 1. Fragmin once or twice daily subcutaneously in the treatment of deep venous thrombosis of the leg.
    Holmoström M; Berglund MC; Granquist S; Bratt G; Törnebohm E; Lockner D
    Thromb Res; 1992 Jul; 67(1):49-55. PubMed ID: 1332213
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Two daily subcutaneous injections of fragmin as compared with intravenous standard heparin in the treatment of deep venous thrombosis (DVT).
    Bratt G; Aberg W; Johansson M; Törnebohm E; Granqvist S; Lockner D
    Thromb Haemost; 1990 Dec; 64(4):506-10. PubMed ID: 1964751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of once-daily subcutaneous Fragmin with continuous intravenous unfractionated heparin in the treatment of deep vein thrombosis.
    Lindmarker P; Holmström M; Granqvist S; Johnsson H; Lockner D
    Thromb Haemost; 1994 Aug; 72(2):186-90. PubMed ID: 7831649
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical experiences in the administration of a low molecular weight heparin (Fragmin, Kabi-Vitrum) to healthy volunteers and in the treatment of established deep venous thrombosis.
    Bratt GA; Törnebohm E; Johanson M; Aberg W; Granqvist S; Lockner D
    Acta Chir Scand Suppl; 1988; 543():96-100. PubMed ID: 2847465
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Treatment of deep venous thrombosis. Comparative study of a low molecular weight heparin fragment (Fragmin) by the subcutaneous route and standard heparin by the continuous intravenous route. A multicenter study].
    Aiach M; Fiessinger JN; Vitoux JF; Derlon A; Grollier G; Le Querrec A; Gouault-Heilmann M; Huet Y; Franco A; Polack B; Pouzol P; Dubois A; Schved JF; Boneu B; Guittard J; Sie P; Heilmann JJ; Kher A; Haye I
    Rev Med Interne; 1989; 10(4):375-81. PubMed ID: 2552552
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Once-daily subcutaneous dalteparin, a low molecular weight heparin, for the initial treatment of acute deep vein thrombosis.
    Fiessinger JN; Lopez-Fernandez M; Gatterer E; Granqvist S; Kher A; Olsson CG; Söderberg K
    Thromb Haemost; 1996 Aug; 76(2):195-9. PubMed ID: 8865530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Treatment of deep venous thrombosis with low molecular weight heparin (Fragmin)].
    Nesvold A; Ly B; Abildgaard U; Stiris M
    Tidsskr Nor Laegeforen; 1991 Nov; 111(27):3296-7. PubMed ID: 1659751
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of subcutaneous low-molecular-weight heparin with warfarin sodium for prophylaxis against deep-vein thrombosis after hip or knee implantation.
    Hull R; Raskob G; Pineo G; Rosenbloom D; Evans W; Mallory T; Anquist K; Smith F; Hughes G; Green D
    N Engl J Med; 1993 Nov; 329(19):1370-6. PubMed ID: 8413432
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk factors and coagulation parameters in relationship to phlebographic response and clinical outcome in the treatment of acute deep vein thrombosis.
    Breddin HK; Kadziola Z; Scully M; Nakov R; Misselwitz F; Kakkar VV
    Thromb Haemost; 2003 Feb; 89(2):272-7. PubMed ID: 12574806
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subcutaneous low molecular weight heparin versus subcutaneous unfractionated heparin in the treatment of deep vein thrombosis: a Polish multicenter trial.
    Lopaciuk S; Meissner AJ; Filipecki S; Zawilska K; Sowier J; Ciesielski L; Bielawiec M; Glowinski S; Czestochowska E
    Thromb Haemost; 1992 Jul; 68(1):14-8. PubMed ID: 1325076
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dosage, anticoagulant, and antithrombotic effects of heparin and low-molecular-weight heparin in the treatment of deep vein thrombosis.
    Harenberg J; Stehle G; Blauth M; Huck K; Mall K; Heene DL
    Semin Thromb Hemost; 1997; 23(1):83-90. PubMed ID: 9156415
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease.
    Merli G; Spiro TE; Olsson CG; Abildgaard U; Davidson BL; Eldor A; Elias D; Grigg A; Musset D; Rodgers GM; Trowbridge AA; Yusen RD; Zawilska K;
    Ann Intern Med; 2001 Feb; 134(3):191-202. PubMed ID: 11177331
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of a low molecular weight heparin administered intravenously or subcutaneously in comparison with intravenous unfractionated heparin in the treatment of deep venous thrombosis. Certoparin-Study Group.
    Kirchmaier CM; Wolf H; Schäfer H; Ehlers B; Breddin HK
    Int Angiol; 1998 Sep; 17(3):135-45. PubMed ID: 9821025
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of a low-molecular-weight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis.
    Breddin HK; Hach-Wunderle V; Nakov R; Kakkar VV;
    N Engl J Med; 2001 Mar; 344(9):626-31. PubMed ID: 11228276
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomised trial of subcutaneous low molecular weight heparin (CY 216) compared with intravenous unfractionated heparin in the treatment of deep vein thrombosis. A collaborative European multicentre study.
    Thromb Haemost; 1991 Mar; 65(3):251-6. PubMed ID: 1646490
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RD heparin compared with warfarin for prevention of venous thromboembolic disease following total hip or knee arthroplasty. RD Heparin Arthroplasty Group.
    J Bone Joint Surg Am; 1994 Aug; 76(8):1174-85. PubMed ID: 8056798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravenous and subcutaneous administration of Fragmin in deep venous thrombosis.
    Lockner D; Bratt G; Törnebohm E; Aberg W; Granqvist S
    Haemostasis; 1986; 16 Suppl 2():25-9. PubMed ID: 3744133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic application of subcutaneous low-molecular-weight heparin in acute venous thrombosis.
    Harenberg J; Huck K; Bratsch H; Stehle G; Dempfle CE; Mall K; Blauth M; Usadel KH; Heene DL
    Haemostasis; 1990; 20 Suppl 1():205-19. PubMed ID: 1964663
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of low molecular weight heparin (dalteparin), once daily, for the treatment of deep vein thrombosis. A feasibility and health economic study in an outpatient setting. Swedish Venous Thrombosis Dalteparin Trial Group.
    Lindmarker P; Holmström M
    J Intern Med; 1996 Dec; 240(6):395-401. PubMed ID: 9010387
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A fixed-dose combination of low molecular weight heparin with dihydroergotamine versus adjusted-dose unfractionated heparin in the prevention of deep-vein thrombosis after total hip replacement.
    Horbach T; Wolf H; Michaelis HC; Wagner W; Hoffmann A; Schmidt A; Beck H
    Thromb Haemost; 1996 Feb; 75(2):246-50. PubMed ID: 8815569
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.